Guangzhou Huli Technology dba Fantasy Face: FDA Letter 722228

Updated August 23, 2026

Guangzhou Huli Technology, doing business as Fantasy Face, received FDA warning letter 722228, dated March 31, 2026 and posted April 7, 2026 — one of seven letters to research-peptide sellers that day. The letter names a single recipient at a Chicago, Illinois location; some secondary summaries have counted the two names as two recipients.

One recipient, not two

The point of this record is clerical. "Guangzhou Huli Technology" is the registered company name on letter 722228; "Fantasy Face" is the name it did business under. They designate one recipient on one letter. Some secondary summaries of the March 31, 2026 batch have listed the two names as separate recipients, which inflates the batch count from seven to eight and implies a letter that does not exist. Anyone reconciling press coverage against FDA's own index should match on the letter number: there is a 722228, and there is nothing else under either name in this batch.

The confusion is specific to how the recipient line reads. Of the seven letters, five name a single entity. Two carry a registered name plus a dba — Lovega LLC dba Pink Pony Peptides on letter 721088, and this one. Summaries that split the registered name from the dba produce the double count. The April 2026 batch record notes this in one paragraph; this page is the dedicated entry.

Record

What the batch letters document

Two findings recur across the seven letters, per the letters and contemporaneous regulatory coverage. The first is descriptive: product pages characterizing the therapeutic effects of the compounds offered. The second is structural: administration supplies listed in the same cart as the compounds, with the composition of the cart itself cited as evidence of intended use. On research-use disclaimers, the batch states the agency's position directly: despite such disclaimers, "evidence obtained from your website establishes that your products are intended to be drugs for human use."

Coded product names are a third batch-level pattern. Coverage of the batch documents "GLP-1 SM" and "GLP-3 RT" as the examples — listings coded in place of standard nomenclature, which the agency read as circumvention rather than caution. The examples are documented at batch level; this index does not attribute them to any single recipient, this one included.

Scope of this entry

This entry records the letter's issuance, its recipient, and the batch-level findings. It records nothing about what the recipient did after the letter — no response, no site change, and no follow-up action appears in the verified record here. The recipient's entity entry in the vendor index carries the same boundary.

Sources

1. FDA Warning Letters index (retrieves the letter to Guangzhou Huli Technology dba Fantasy Face, 722228, by recipient name). fda.gov
2. Policy Canary analysis of the March 31, 2026 batch. policycanary.io
3. Partnership for Safe Medicines, PDF summary of the seven letters (April 7, 2026 posting). safemedicines.org

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.